Cue Biopharma, Inc. Cash Flow Statement
CUE|8 years of annual SEC 10-K data (FY2018-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 8 fiscal years. All figures from audited SEC 10-K filings.
Cue Biopharma, Inc. used $22M in operating cash flow and negative free cash flow of $22M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -7.60 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$26.6M | -$40.7M | -$50.7M | -$53.0M | -$44.2M | -$36.7M | -$39.0M | -$23.2M |
| Depreciation & Amortization | $958.0K | $397.0K | $556.0K | $922.0K | $1.3M | $810.8K | $760.0K | $419.6K |
| Operating Cash Flow | -$21.7M | -$36.3M | -$40.0M | -$41.8M | -$38.8M | -$30.8M | -$26.4M | -$12.1M |
| Capital Expenditures | $177.0K | $66.0K | $0 | $171.0K | $913.0K | $46.4K | $1.9M | $1.0M |
| Free Cash Flow | -$21.9M | -$36.4M | -$40.0M | -$42.0M | -$39.8M | -$30.8M | -$28.3M | -$13.2M |
| Share Buybacks | - | - | $0 | $200.0K | $750.1K | $91.0K | $91.0K | - |
| FCF Margin | -79.6% | -391.9% | -727.9% | -3371.7% | -266.0% | -891.9% | -2473.8% | -1152.8% |